Global Cardiovascular Genetic Testing Market, By Disease (Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Testing Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others) – Industry Trends and Forecast to 2030.
Cardiovascular Genetic Testing Market Analysis and Size
The global cardiovascular genetic testing market is a significant component of the broader genetic testing industry and is focused on identifying genetic factors related to cardiovascular diseases. Cardiovascular genetic testing helps assess an individual's genetic predisposition to cardiovascular diseases, such as coronary artery disease, hypertension, and cardiomyopathies. This information can guide healthcare professionals in tailoring preventive strategies and treatments. Genetic testing can identify individuals at higher risk of developing cardiovascular diseases at an early stage. This allows for more timely interventions and lifestyle modifications to prevent or delay disease progression and due to all these factors, there will be an upsurge in the growth of the global cardiovascular genetic testing market.
Data Bridge Market Research analyses that the global cardiovascular genetic testing market which was USD 7,336.36 million in 2022, expected to reach USD 17,152.16 million by 2030, and is expected to undergo a CAGR of 11.2% during the forecast period 2023-2030. “Inherited cardiomyopathies” dominates the disease segment of the global cardiovascular genetic testing market owing to the growing demand for better methods of bone related treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cardiovascular Genetic Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease (Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, and Others), Technology(Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Testing Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher (U.S.), Daan Gene Co., Ltd. (Canada), F. Hoffmann-La Roche, Ltd. (Switzerland), Genentech, Inc. (U.S.), Genomictree, Inc. (South Korea), HTG Molecular Diagnostics, Inc. (U.S.), Illumina, Inc. (U.S.), Integragen (France), Laboratory Corporation of America Holdings (U.S.), Luminex Corporation (U.S.), Molecular MD Corp. (U.S.), Myriad Genetics, Inc. (U.S.), Natera, Inc. (U.S.), Oxford Biodynamics Plc (U.K), PacBio (U.S.), PerkinElmer Inc. (U.S.), Qiagen (Germany), Thermo Fisher Scientific, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Cardiovascular genetic testing the broader genetic testing industry that focuses on the testing, analysis, and interpretation of an individual's genetic information to identify genetic factors and mutations associated with cardiovascular diseases and conditions. Cardiovascular genetic testing provides insights into an individual's genetic predisposition to various heart and vascular conditions. Cardiomyopathies, arrhythmic disorders, thoracic aortic aneurysms and dissections, and familial hypercholesterolemia (FH) are among the inherited cardiovascular diseases for which genetic testing is instructive and beneficial.
Global Cardiovascular Genetic Testing Market Dynamics
Drivers
- Growing Prevalence of Cardiovascular Diseases
Cardiovascular diseases, including coronary artery disease, hypertension, and heart failure, remain major global health concerns. The increasing prevalence of these conditions has heightened the need for genetic testing to identify at-risk individuals and guide prevention and treatment strategies. Cardiovascular genetic testing can identify genetic factors that increase the risk of heart diseases, even before clinical symptoms appear. This early detection allows for preventive measures and lifestyle modifications to mitigate disease risk.
- Wellness and Preventive Health Initiatives
As preventive healthcare gains importance, individuals are more interested in understanding their genetic risk factors to take proactive measures in maintaining cardiovascular health. Wellness and preventive health initiatives promote awareness of the importance of proactive healthcare. Individuals are becoming more conscious of the need to monitor their health and take preventive measures to reduce the risk of diseases. Preventive healthcare is gaining prominence over reactive healthcare. People are looking for ways to identify health risks early and take action to prevent diseases, including cardiovascular conditions.
Opportunity
- Preventive Healthcare Initiatives and Measures
Preventive healthcare is becoming a priority for individuals and healthcare systems. Genetic testing is a valuable tool for preventive measures, helping individuals make informed decisions about their cardiovascular health. Preventive healthcare initiatives emphasize the importance of early detection and risk assessment. Cardiovascular genetic testing allows individuals to identify their genetic predisposition to heart diseases at an early stage, enabling timely interventions and preventive measures.
Restraint/Challenge
- Ethical and Privacy Concerns
Genetic testing raises ethical questions regarding the privacy and security of individuals genetic information. Concerns about how genetic data may be used or shared can discourage some individuals from participating in testing. Genetic testing involves the collection of highly sensitive personal information, including an individual's genetic code. Concerns about data privacy and security have increased as data breaches and misuse of personal information become more prevalent. Patients may be hesitant to undergo testing if they fear their genetic data could be exposed or misused.
This global cardiovascular genetic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cardiovascular genetic testing market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In November 2020, the FDA expanded the approval of a cancer blood test known as "liquid biopsy," which detects genetic alterations in tumour DNA in the blood and can help match patients to appropriate treatments
- In August 2020, the FDA authorised Guardant360 CDx and FoundationOne Liquid CDx from Guardant Health and Foundation Medicine for use as companion diagnostic tests and general tumour profiling
Global Cardiovascular Genetic Testing Market Scope
The global cardiovascular genetic testing market is segmented on the basis of disease, technology, testing type, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease
- Inherited Cardiomyopathies
- Hypertrophic Cardiomyopathy (HCM)
- Dilated Cardiomyopathy (DCM)
- Arrhythmia
- Aortopathies
- Others
Technology
- Cytogenetic Testing
- Biochemical Testing
- Molecular Testing
Testing Type
- Predictive Testing
- Carrier Testing
- Prenatal and Newborn Testing
- Diagnostic Testing
- Pharmacogenomic Testing
- Others
Application
- Chromosome Analysis
- Genetic Disease Diagnosis
- Cardiovascular Disease Diagnosis
- Others
Global Cardiovascular Genetic Testing Market Regional Analysis/Insights
The global cardiovascular genetic testing market is analysed and market size insights and trends are provided by country, disease, technology, testing type, and application as referenced above.
The countries covered in the global cardiovascular genetic testing market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global cardiovascular genetic testing market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having chronic diseases.
Asia-Pacific is expected to witness significant growth in the global cardiovascular genetic testing market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for chronic diseases, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global cardiovascular genetic testing market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global cardiovascular genetic testing market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on global cardiovascular genetic testing market. The data is available for the historic period of 2015-2020.
Competitive Landscape and Global Cardiovascular Genetic Testing Market Share Analysis
The global cardiovascular genetic testing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global cardiovascular genetic testing market.
Some of the major players operating in the global cardiovascular genetic testing market are:
- Abbott (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Danaher (U.S.)
- Daan Gene Co., Ltd. (Canada)
- F. Hoffmann-La Roche, Ltd. (Switzerland)
- Genentech, Inc. (U.S.)
- Genomictree, Inc. (South Korea)
- HTG Molecular Diagnostics, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Integragen (France)
- Laboratory Corporation of America Holdings (U.S.)
- Luminex Corporation (U.S.)
- Molecular MD Corp. (U.S.)
- Myriad Genetics, Inc. (U.S.)
- Natera, Inc. (U.S.)
- Oxford Biodynamics Plc (U.K)
- PacBio (U.S.)
- PerkinElmer Inc. (U.S.)
- Qiagen (Germany)
- Thermo Fisher Scientific, Inc. (U.S.)
SKU-